December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.84 +0.26 (+1.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Emerges as a Strong Value Investing Opportunity
PACIRA BIOSCIENCES (PCRX) is a strong value stock with undervalued P/E ratios, solid profitability, and stable finances, offering potential for long-term investors. 
Via Chartmill
Pacira (PCRX) Q2 Revenue Rises 1.7%
Via The Motley Fool
Pacira BioSciences Inc (NASDAQ:PCRX) Reports Mixed Q2 2025 Earnings with EPS Beat but Revenue Miss
Pacira BioSciences (PCRX) reported mixed Q2 2025 results, with EPS beating estimates but revenue missing. Shares were flat post-release as investors weighed the performance. The company highlighted... 
Via Chartmill
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Insights Ahead: Pacira BioSciences's Quarterly Earnings
 
Via Benzinga
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock Worth Considering
PACIRA BIOSCIENCES (NASDAQ:PCRX) offers an undervalued opportunity with strong profitability, manageable debt, and steady growth, making it a candidate for value investors. 
Via Chartmill
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Preview: Pacira BioSciences's Earnings
 
Via Benzinga
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts
 
Via Benzinga
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock with Strong Fundamentals
PACIRA BIOSCIENCES (PCRX) appears undervalued with strong profitability and steady growth, making it a potential candidate for value investors. 
Via Chartmill
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock with Solid Fundamentals
PACIRA BIOSCIENCES (PCRX) appears undervalued with strong profitability, steady growth, and reasonable financial health, making it a candidate for value investors. 
Via Chartmill
Where Pacira BioSciences Stands With Analysts
 
Via Benzinga
Don't overlook PACIRA BIOSCIENCES INC (NASDAQ:PCRX)—a stock with solid growth prospects and a reasonable valuation.
Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): An Affordable Growth Stock Worth Watching
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): An Affordable Growth Stock Worth Watching 
Via Chartmill
Earnings Scheduled For February 27, 2025
 
Via Benzinga
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals.
PACIRA BIOSCIENCES INC may be an undervalued stock option. NASDAQ:PCRX retains a strong financial foundation and an attractive price tag. 
Via Chartmill
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
PACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock which is not overvalued.
Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
Pacira Biosciences Stock Rises On Patent Litigation Settlement: Retail Sentiment Soars
RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and... 
Via Stocktwits
Topics Intellectual Property
Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps
Pacira settles Exparel patent cases, grants Fresenius phased license for generic sales beginning in 2030, with full access no earlier than 2039. 
Via Benzinga
Topics Intellectual Property
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Forecasting The Future: 8 Analyst Projections For Pacira BioSciences
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Pacira Biosciences Stock Surges After-Hours On Exparel Patent Settlement: Retail Investors Rejoice
As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030. 
Via Stocktwits
Topics Intellectual Property Lawsuit
Wondering what's happening in today's after-hours session?
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals.
PACIRA BIOSCIENCES INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:PCRX showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX
The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility. 
Via Talk Markets
Topics Stocks / Equities
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals.
PACIRA BIOSCIENCES INC has a stellar value proposition. NASDAQ:PCRX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate
Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.